Physician profile
Ignacio Montes
NPI 1568435204
$1,046.43
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.11 · 2020: $55.75 · 2021: $126 · 2022: $48.89 · 2023: $270 · 2024: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $148.55 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $148.40 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $80.59 | 2020-2024 | Wainua |
| Celgene Corporation | $51.60 | 2023-2024 | Pomalyst |
| Pfizer INC. | $51.28 | 2024 | |
| Eisai INC. | $50.76 | 2021-2024 | |
| Janssen Biotech, INC. | $37.91 | 2021-2023 | Darzalex, Imbruvica |
| Glaxosmithkline, LLC. | $31.74 | 2024 | Ojjaara |
| Tempus Ai, INC | $28.96 | 2024 | |
| Daiichi Sankyo INC. | $26.70 | 2023 | Enhertu |
| Genmab U.S., INC. | $25.15 | 2024 | Tivdak |
| Tosoh Bioscience, INC. | $25.00 | 2019 | |
| Sun Pharmaceutical Industries INC. | $22.70 | 2023 | Yonsa, Odomzo |
| Adaptive Biotechnologies Corporation | $21.48 | 2024 | Clonoseq |
| E.R. Squibb & Sons, L.L.C. | $21.28 | 2023 | Camzyos |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $20.19 | 2023 | |
| Novo Nordisk INC | $19.08 | 2024 | |
| Seagen INC. | $18.17 | 2022 | |
| Pharmaessentia USA Corporation | $17.65 | 2022 | |
| Puma Biotechnology, INC. | $17.60 | 2023 | |
| Cti Biopharma Corp. | $17.25 | 2023 | Vonjo |
| Adc Therapeutics America, INC. | $17.07 | 2024 | |
| Stemline Therapeutics INC. | $16.75 | 2020 | |
| Fennec Pharmaceuticals, INC. | $16.29 | 2023 | Pedmark |
| Amgen INC. | $15.99 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $15.88 | 2024 | Sancuso |
| Abbvie INC. | $15.76 | 2024 | |
| Genzyme Corporation | $15.75 | 2023 | |
| Morphosys, US INC. | $13.41 | 2021 | |
| Pharmacosmos Therapeutics INC. | $12.92 | 2021 | |
| Global Blood Therapeutics, INC. | $12.65 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ignacio Montes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.